Provided herein are inhibitors of TNF-?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-? inhibitory compounds for the treatment of diseases or disorders.

The present invention relates to compounds of the formula (I), ##STR00001##
to the use of compounds of the formula (I) in electronic devices, and to electronic devices containing one or more compounds of the formula (I). The invention furthermore relates to preparation processes for compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).

The present invention relates to compounds of the formula (I), ##STR00001##
to the use of compounds of the formula (I) in electronic devices, and to electronic devices containing one or more compounds of the formula (I). The invention furthermore relates to preparation processes for compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

##STR00001##

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

##STR00001##

Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

A compound with the Formula (I):

A-B-C(I)

wherein A is of the following formula:

##STR00001##

where X.sup.1 is N
B is of formula (B-1) or (B-2)

##STR00002##

and C is selected from the group consisting of optionally substituted C.sub.6-10 carboaryl, C.sub.5-6 heteroaryl and C.sub.5-10 heterocyclyl and their use as PCSK9 inhibitors.